H3 Biomedicine marks the opening of its Kendall Square office
H3 Biomedicine Inc., a start-up focused on cancer treatments based on genetics, is officially unveiling its new 24,000-square-foot office in Cambridge today, another sign of growth at Kendall Square. H3 Biomedicine currently employs 30 staffers and it looks to add another 40 over the next 12 months. The company’s scientific founders include Stuart L. Schreiber and Todd R. Golub, both of the Broad Institute of Harvard and MIT. H3 Biomedicne has $200 million in research funding from Eisai Inc., a Japanese pharmaceutical company.